{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T19:24:00Z","timestamp":1780341840051,"version":"3.54.1"},"reference-count":21,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.vaccine.2020.03.009","type":"journal-article","created":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T08:34:29Z","timestamp":1584174869000},"page":"3300-3304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8914-7073","authenticated-orcid":false,"given":"Muriel","family":"Feyssaguet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Berthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Helle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Povey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Ravault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Carryn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Gillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Di Paolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.03.009_b0005","doi-asserted-by":"crossref","first-page":"15016","DOI":"10.1038\/nrdp.2015.16","article-title":"Varicella zoster virus infection","volume":"1","author":"Gershon","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.vaccine.2020.03.009_b0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jcv.2006.01.017","article-title":"European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus","volume":"36","author":"de Ory","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.vaccine.2020.03.009_b0015","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00183-12","article-title":"Evaluation of three commercial varicella-zoster virus IgG enzyme-linked immunosorbent assays in comparison to the fluorescent-antibody-to-membrane-antigen test","volume":"19","author":"Sauerbrei","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.03.009_b0020","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/jmv.1890320310","article-title":"Sensitive enzyme-linked immunosorbent assay for antibody to varicella-zoster virus using purified VZV glycoprotein antigen","volume":"32","author":"Wasmuth","year":"1990","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2020.03.009_b0025","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older","volume":"217","author":"Cunningham","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.009_b0030","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.vaccine.2017.11.019","article-title":"Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study","volume":"36","author":"Lal","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.009_b0035","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1080\/21645515.2018.1442162","article-title":"Persistence of immune response to an adjuvanted varicella-zoster virus subunit vaccine for up to year nine in older adults","volume":"14","author":"Schwarz","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.03.009_b0040","unstructured":"Cohen JI, Straus SE, Arvin AM. 70 Varicella-zoster virus. In: Knipe DM, Howley PM, editors. Fields virology, 5th ed., vol. 2. Lippincott Williams & Wilkins, Philadelphia, PA2007. p. 2773\u201318."},{"key":"10.1016\/j.vaccine.2020.03.009_b0045","series-title":"The predominant varicella-zoster virus gE and gI glycoprotein complex. Structure-function relationships of human pathogenic viruses","first-page":"195","author":"Grose","year":"2002"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.03.009_b0050","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1086\/522123","article-title":"Humoral and cellular immunity to varicella-zoster virus: an overview","volume":"197","author":"Arvin","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.009_b0055","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12887-019-1425-7","article-title":"Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study","volume":"19","author":"Faust","year":"2019","journal-title":"BMC Pediatr"},{"key":"10.1016\/j.vaccine.2020.03.009_b0060","unstructured":"National Institute for Biological Standards and Control. British Working Standard for varicella-zoster antibodies. NIBSC code: 90\/690. Instructions for use (Version 7.0, Dated 19\/12\/2013). NIBSC, Potters Bar, Hertfordshire, EN6 3QG, United Kingdom. http:\/\/www.nibsc.org\/documents\/ifu\/90-690.pdf. [last accessed September 15, 2019]."},{"key":"10.1016\/j.vaccine.2020.03.009_b0065","unstructured":"National Institute for Biological Standards and Control. The first international standard for varicella zoster immunoglobulin. NIBSC code: W1044. Instructions for use (Version 4.0, Dated 26\/04\/2013). http:\/\/www.nibsc.org\/documents\/ifu\/W1044.pdf. [last accessed September 15, 2019]."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2020.03.009_b0070","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1093\/infdis\/166.Supplement_1.S35","article-title":"Cell-mediated immunity to varicella-zoster virus","volume":"166","author":"Arvin","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.009_b0075","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1093\/infdis\/165.5.852","article-title":"Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine","volume":"165","author":"Sharp","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.009_b0080","unstructured":"Varilrix. Summary of product characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/1676\/smpc. [last accessed September 3, 2019]."},{"key":"10.1016\/j.vaccine.2020.03.009_b0085","unstructured":"Shingrix. Summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/shingrix-epar-product-information_en.pdf. [last accessed September 3, 2019]."},{"key":"10.1016\/j.vaccine.2020.03.009_b0090","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1128\/JCM.00719-06","article-title":"Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen","volume":"44","author":"Sauerbrei","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.03.009_b0095","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1007\/s00253-016-7821-0","article-title":"Evaluation of immunity to varicella zoster virus with a novel double antigen sandwich enzyme-linked immunosorbent assay","volume":"100","author":"Liu","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2020.03.009_b0100","first-page":"991","article-title":"Reactogenicity and immunogenicity of a live-attenuated refrigerator-stable varicella vaccine (OKA strain) in healthy seronegative subjects age 10 months to 12 years","volume":"40","author":"Hadinegoro","year":"2009","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.vaccine.2020.03.009_b0105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12887-016-0546-5","article-title":"Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial","volume":"16","author":"Prymula","year":"2016","journal-title":"BMC Pediatr"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303522?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20303522?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:42:30Z","timestamp":1759401750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20303522"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":21,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S0264410X20303522"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.009","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of a glycoprotein E-based ELISA with a varicella-zoster whole-virus ELISA for the quantification of varicella vaccine immune responses in young children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 GlaxoSmithKline Biologicals S.A. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}